An Overview of the Clinical Efficacy and Safety of Tissue Selective Estrogen Complex: From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials / 고신대학교의과대학학술지
Kosin Medical Journal
;
: 5-16, 2017.
Article
in English
| WPRIM
| ID: wpr-149286
ABSTRACT
Hormone therapy (HT) is the most effective treatment for menopausal symptoms, and reduces both spinal and non-spinal postmenopausal osteoporotic fractures. However, a Women's Health Initiative (WHI) trial revealed that progestin-containing HT is associated with higher incidences of breast cancer and coronary heart disease than those associated with placebo. Tissue selective estrogen complex (TSEC) is a novel progestin-free HT option composed of conjugated estrogens (CE) and a selective estrogen receptor modulator. CE at a dose of 0.45 mg combined with 20 mg of bazedoxifene was the first TSEC medication approved in the United States and Korea for women with moderate to severe menopause-related vasomotor symptoms (VMS) and for preventing postmenopausal osteoporosis. This review summarizes the clinical efficacy, safety, and tolerability of TSEC as obtained from the five SMART clinical trials.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
United States
/
Breast Neoplasms
/
Menopause
/
Osteoporosis, Postmenopausal
/
Incidence
/
Women's Health
/
Treatment Outcome
/
Estrogens, Conjugated (USP)
/
Coronary Disease
/
Selective Estrogen Receptor Modulators
Type of study:
Controlled clinical trial
/
Incidence study
/
Prognostic study
Limits:
Female
/
Humans
Country/Region as subject:
North America
/
Asia
Language:
English
Journal:
Kosin Medical Journal
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS